Form 4: Xeris Biopharma CFO Exercises Stock Options and Acquires Shares

Xeris Biopharma's Chief Financial Officer, Steven Pieper, exercised stock options and acquired 19,483 shares of common stock at $1.55 per share on November 22, 2024.

Summary

• Steven Pieper, the Chief Financial Officer of Xeris Biopharma Holdings, Inc., exercised stock options on November 22, 2024.
• He acquired 19,483 shares of common stock at a price of $1.55 per share.
• The transaction resulted in Mr. Pieper owning a total of 1,441,820 shares of common stock directly.
• The stock options exercised were granted under the company's 2011 Stock Option/Stock Issuance Plan.
• The options were granted on February 7, 2017 and June 12, 2017 and vested in four equal installments.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it reports a standard transaction. It is neither particularly positive nor negative for the company's outlook.

Positives

• The exercise of stock options by the CFO could be seen as a positive sign of confidence in the company's future performance.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It reflects the compensation structure for executives.

Comparison to Industry Standards

• Stock option exercises are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of the options, in four equal installments, is a common practice to incentivize long-term performance.
• The price of $1.55 per share is the exercise price of the options, not necessarily the current market price of the stock.

Stakeholder Impact

• The transaction increases the CFO's stake in the company, aligning his interests with those of shareholders.

Key Dates

Keywords

Xeris Biopharma, Stock Options, SEC Form 4, Steven Pieper, CFO, Share Acquisition, Insider Trading